THE 4 F-5 D INTERACTIONS in SAMARIUM, GADOLINIUM and TERBIUM N
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Gadolinium Information
Gadolinium Information Gadolinium contrast agents are frequently utilized during MRI examinations in order to improve the exam and interpretation. They are not always needed. Your radiologist will determine whether or not gadolinium contrast is needed for your MRI examination. Gadolinium contrast agents are quickly eliminated from the body in healthy individuals. With normal functioning kidneys, the retention of gadolinium in soft tissues of the body is very small and may not even be detectable. However, some patients who receive multiple doses of contrast, including pregnant women and children, might be at increased risk of gadolinium remaining in the body for longer periods of time. To date, there are no known harmful effects of gadolinium remaining in the body for long periods of time in patients who have normal kidneys. In patients who have poorly functioning kidneys, a condition called nephrogenic systemic sclerosis (NSF) can occur. This causes debilitating thickening of the skin and other tissues. This only occurs in patients with poorly functioning kidneys. Your kidney function will be checked prior to receiving gadolinium contrast agent if needed. Other side-effects can occur even in patients with healthy kidneys. Some patients report pain, tiredness, and muscle aches after receiving gadolinium contrast but these conditions have not been directly linked to the administration of the gadolinium. Allergic reactions can also occur, as with any drug. If you have questions regarding your MRI examination today, please ask your MRI Technologist. MEDICATION GUIDE MULTIHANCE® (məl-tē-han(t)s) (gadobenate dimeglumine) Injection for intravenous use What is MULTIHANCE? • MULTIHANCE is a prescription medicine called a gadolinium-based contrast agent (GBCA). -
The Development of the Periodic Table and Its Consequences Citation: J
Firenze University Press www.fupress.com/substantia The Development of the Periodic Table and its Consequences Citation: J. Emsley (2019) The Devel- opment of the Periodic Table and its Consequences. Substantia 3(2) Suppl. 5: 15-27. doi: 10.13128/Substantia-297 John Emsley Copyright: © 2019 J. Emsley. This is Alameda Lodge, 23a Alameda Road, Ampthill, MK45 2LA, UK an open access, peer-reviewed article E-mail: [email protected] published by Firenze University Press (http://www.fupress.com/substantia) and distributed under the terms of the Abstract. Chemistry is fortunate among the sciences in having an icon that is instant- Creative Commons Attribution License, ly recognisable around the world: the periodic table. The United Nations has deemed which permits unrestricted use, distri- 2019 to be the International Year of the Periodic Table, in commemoration of the 150th bution, and reproduction in any medi- anniversary of the first paper in which it appeared. That had been written by a Russian um, provided the original author and chemist, Dmitri Mendeleev, and was published in May 1869. Since then, there have source are credited. been many versions of the table, but one format has come to be the most widely used Data Availability Statement: All rel- and is to be seen everywhere. The route to this preferred form of the table makes an evant data are within the paper and its interesting story. Supporting Information files. Keywords. Periodic table, Mendeleev, Newlands, Deming, Seaborg. Competing Interests: The Author(s) declare(s) no conflict of interest. INTRODUCTION There are hundreds of periodic tables but the one that is widely repro- duced has the approval of the International Union of Pure and Applied Chemistry (IUPAC) and is shown in Fig.1. -
Gadolinium Speciation
Gadolinium Speciation Peter Caravan Martinos Center for Biomedical Imaging Institute for Innovation in Imaging Massachusetts General Hospital and Harvard Medical School Conflicts of Interest Stock ownership (>5%): Reveal Pharmaceuticals; Collagen Medical; Factor 1A LLC. Research grants: Pfizer; Pliant Pharmaceuticals; Biogen; Agilent; Pharmakea; Siemens. Consulting: Guerbet; Bayer; Collagen Medical; UCB Biopharma; Pfizer. What do we mean by speciation? What is the chemical form of the gadolinium in tissue? Chelated Gd Dissociated Gd The GBCA remains intact Dissociation of the GBCA Gd3+ ion Is Gd bound to a low molecular weight ligand? Is Gd part of some inorganic material like hydroxyapatite? Is Gd bound to a macromolecule? If so, which one? Where is the Gd distributed within tissue? Extra vs intracellular? In which cellular compartments? Why do we care about speciation? • The chemical form of Gd may inform its potential toxicity • Mineralized, insoluble Gd may be less toxic than soluble protein bound Gd (hypothesis) • The chemical form may also inform whether the Gd will be ultimately eliminated. Intact chelate may be expected to eventually clear the body (hypothesis). • The chemical form and location may guide chelation therapy strategies. Hierarchy of relevance of the data Human in vivo Human ex vivo Animal in vivo Animal ex vivo Solutions To model ex vivo Water solutions Tweedle MF. Gadolinium deposition: Is it chelated or dissociated gadolinium? How can we tell? Magn Reson Imaging. 2016;34(10):1377–82. How do GBCAs differ • Thermodynamics: -
Preliminary Estimates of the Quantities of Rare-Earth Elements Contained in Selected Products and in Imports of Semimanufactured Products to the United States, 2010
Preliminary Estimates of the Quantities of Rare-Earth Elements Contained in Selected Products and in Imports of Semimanufactured Products to the United States, 2010 By Donald I. Bleiwas and Joseph Gambogi Open-File Report 2013–1072 U.S. Department of the Interior U.S. Geological Survey U.S. Department of the Interior KEN SALAZAR, Secretary U.S. Geological Survey Suzette M. Kimball, Acting Director U.S. Geological Survey, Reston, Virginia: 2013 For more information on the USGS—the Federal source for science about the Earth, its natural and living resources, natural hazards, and the environment—visit http://www.usgs.gov or call 1–888–ASK–USGS For an overview of USGS information products, including maps, imagery, and publications, visit http://www.usgs.gov/pubprod To order other USGS information products, visit http://store.usgs.gov Suggested citation: Bleiwas, D.I., and Gambogi, Joseph, 2013, Preliminary estimates of the quantities of rare-earth elements contained in selected products and in imports of semimanufactured products to the United States, 2010: U.S. Geological Survey Open–File Report 2013–1072, 14 p., http://pubs.usgs.gov/of/2013/1072/. Any use of trade, firm, or product names is for descriptive purposes only and does not imply endorsement by the U.S. Government. Although this information product, for the most part, is in the public domain, it also may contain copyrighted materials as noted in the text. Permission to reproduce copyrighted items must be secured from the copyright owner. Cover. Left: Aerial photograph of Molycorp, Inc.’s Mountain Pass rare-earth oxide mining and processing facilities in Mountain Pass, California. -
ACR Manual on Contrast Media
ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions. -
Cerium Oxide Nanoparticles and Gadolinium Integration
Linköping Studies in Science and Technology Dissertation No. 1997 Peter Eriksson Peter FACULTY OF SCIENCE AND ENGINEERING Linköping Studies in Science and Technology, Dissertation No. 1997, 2019 Cerium Oxide Nanoparticles Department of Physics, Chemistry and Biology (IFM) Linköping University SE-581 83 Linköping, Sweden and Gadolinium Integration Cerium Oxide Integration Nanoparticles and Gadolinium Synthesis, Characterization and Biomedical Applications www.liu.se Peter Eriksson 2019 Linköping Studies in Science and Technology Dissertation No. 1997 Cerium Oxide Nanoparticles and Gadolinium Integration Synthesis, Characterization and Biomedical Applications Peter Eriksson Applied Physics Department of Physics, Chemistry & Biology Linköping University, Sweden Linköping 2019 Front cover: A cerium oxide nanoparticle with integrated gadolinium. Back cover: Cross-section of a gadolinium-cerium oxide nanoparticle and its displayed theragnostic properties: left) cerium undergo redox-reactions to scavenge reactive oxygen species and right) gadolinium shorten the T1-relaxation time of nuclei spins in water molecules. During the course of the research underlying this thesis, Peter Eriksson was enrolled in Forum Scientium, a multidisciplinary doctoral programme at Linköping University, Sweden. © Copyright 2019 Peter Eriksson, unless otherwise noted Peter Eriksson Cerium Oxide Nanoparticles and Gadolinium Integration; Synthesis, Characterization and Biomedical Applications ISBN: 978-91-7685-029-9 ISSN: 0345-7524 Linköping Studies in Science and Technology, -
To Ytterbium(II)
University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Masters Theses Graduate School 12-2008 The Use of Lanthanide Triflates as a Method for Reducing Ytterbium(III) to Ytterbium(II) Latasha Michelle Garrett University of Tennessee - Knoxville Follow this and additional works at: https://trace.tennessee.edu/utk_gradthes Part of the Chemistry Commons Recommended Citation Garrett, Latasha Michelle, "The Use of Lanthanide Triflates as a Method for Reducing tterbium(III)Y to Ytterbium(II). " Master's Thesis, University of Tennessee, 2008. https://trace.tennessee.edu/utk_gradthes/378 This Thesis is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Masters Theses by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. To the Graduate Council: I am submitting herewith a thesis written by Latasha Michelle Garrett entitled "The Use of Lanthanide Triflates as a Method for Reducing tterbium(III)Y to Ytterbium(II)." I have examined the final electronic copy of this thesis for form and content and recommend that it be accepted in partial fulfillment of the equirr ements for the degree of Master of Science, with a major in Chemistry. George Schweitzer, Major Professor We have read this thesis and recommend its acceptance: Ben Xue, Jamie Adcock Accepted for the Council: Carolyn R. Hodges Vice Provost and Dean of the Graduate School (Original signatures are on file with official studentecor r ds.) To the Graduate Council: I am submitting herewith a thesis written by Latasha Michelle Garrett entitled “The Use of Lanthanide Triflates as a Method for Reducing Ytterbium(III) to Ytterbium(II).” I have examined the final electronic copy of this thesis for form and content and recommend that it be accepted in partial fulfillment of the requirements for the degree of Master of Science, with a major in chemistry. -
Periodic Table 1 Periodic Table
Periodic table 1 Periodic table This article is about the table used in chemistry. For other uses, see Periodic table (disambiguation). The periodic table is a tabular arrangement of the chemical elements, organized on the basis of their atomic numbers (numbers of protons in the nucleus), electron configurations , and recurring chemical properties. Elements are presented in order of increasing atomic number, which is typically listed with the chemical symbol in each box. The standard form of the table consists of a grid of elements laid out in 18 columns and 7 Standard 18-column form of the periodic table. For the color legend, see section Layout, rows, with a double row of elements under the larger table. below that. The table can also be deconstructed into four rectangular blocks: the s-block to the left, the p-block to the right, the d-block in the middle, and the f-block below that. The rows of the table are called periods; the columns are called groups, with some of these having names such as halogens or noble gases. Since, by definition, a periodic table incorporates recurring trends, any such table can be used to derive relationships between the properties of the elements and predict the properties of new, yet to be discovered or synthesized, elements. As a result, a periodic table—whether in the standard form or some other variant—provides a useful framework for analyzing chemical behavior, and such tables are widely used in chemistry and other sciences. Although precursors exist, Dmitri Mendeleev is generally credited with the publication, in 1869, of the first widely recognized periodic table. -
Evaluating the Potential of Chelation Therapy to Prevent and Treat
www.nature.com/scientificreports OPEN Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from Received: 29 December 2017 Accepted: 23 February 2018 MRI contrast agents Published: xx xx xxxx Julian A. Rees1, Gauthier J.-P. Deblonde1, Dahlia D. An 1, Camille Ansoborlo1, Stacey S. Gauny1 & Rebecca J. Abergel1,2 Several MRI contrast agent clinical formulations are now known to leave deposits of the heavy metal gadolinium in the brain, bones, and other organs of patients. This persistent biological accumulation of gadolinium has been recently recognized as a deleterious outcome in patients administered Gd- based contrast agents (GBCAs) for MRI, prompting the European Medicines Agency to recommend discontinuing the use of over half of the GBCAs currently approved for clinical applications. To address this problem, we fnd that the orally-available metal decorporation agent 3,4,3-LI(1,2- HOPO) demonstrates superior efcacy at chelating and removing Gd from the body compared to diethylenetriaminepentaacetic acid, a ligand commonly used in the United States in the GBCA Gadopentetate (Magnevist). Using the radiotracer 153Gd to obtain precise biodistribution data, the results herein, supported by speciation simulations, suggest that the prophylactic or post-hoc therapeutic use of 3,4,3-LI(1,2-HOPO) may provide a means to mitigate Gd retention in patients requiring contrast-enhanced MRI. Te use of gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) has been ubiqui- tous in radiology for nearly three decades1. Recently however, it has come to light that the suboptimal biological stability of GBCAs can lead to accumulation of Gd in patients’ bone and brain tissue, as well as to kidney damage and associated systemic conditions due to compromised renal function2–4. -
Europium-DTPA: a Gadolinium Analogue Traceable by Fluorescence Microscopy
1137 Dyke Award Europium-DTPA: A Gadolinium Analogue Traceable by Fluorescence Microscopy Allen D. Elster1 A lanthanide series chelate, europium(Eu)-DTPA, was synthesized to serve as a Susan C. Jackels2 histochemical analogue for the widely used MR contrast agent gadolinium(Gd)-DTPA. Nina S. Allen3 Eu and Gd, being neighboring elements on the periodic table, share many fundamental Ron C. Marrache2 properties, including ionic radius, valence, and chemical reactivity. Eu-DTPA, however, possesses one important physical property not shared by Gd-DTPA: luminescence under ultraviolet light. The feasibility of detecting Eu-DTPA in animal tissues under fluorescence microscopy was systematically evaluated and documented. Distinctive orange-red luminescence of Eu-DTPA could be observed in the kidneys, livers, dura, choroid, and pituitary glands of rats after intravascular injection. No lumi nescence was detected in areas of brain beyond an intact blood-brain barrier. When the brain was locally injured by an experimental laceration, however, leakage of Eu-DTPA was detected. Electron probe microanalysis confirmed the parallel presence or absence of simultaneously injected Eu-DTPA and Gd-DTPA in all tissues studied. Fluorescence microscopy with Eu-DTPA has thus been validated as a method for tracing the distri bution of Gd-DTPA at the microscopic level. AJNR 10:1137-1144, November/December 1989 The recent development of paramagnetic MR contrast agents such as gadolinium (Gd)-DTPA has been received by the radiologic community with justifiable enthu siasm. Like their iodinated counterparts in CT, MR contrast agents appear to offer increased sensitivity and specificity for detecting and characterizing a number of diseases affecting the nervous system [1-11 ]. -
Enriched Gadolinium As Burnable Absorber For
PHYSOR 2004 – The Physics of Fuel Cycles and Advanced Nuclear Systems: Global Developments Chicago, Illinois, April 25-29, 2004, on CD-ROM, American Nuclear Society, Lagrange Park, IL. (2004) Enriched Gadolinium as Burnable Absorber for PWR Klaes-Håkan Bejmer*1 and Ola Seveborn2 1Vattenfall Bränsle AB, S-162 87 Stockholm, Sweden 2Sernanders väg 5-518, S-752 61 Uppsala, Sweden Abstract This paper is a summary of a master of thesis work in reactor physics made by Ola Seveborn. The work was done at Vattenfall Bränsle AB and Ola was guided through the work by the corresponding author of this paper. The results presented are calculations for Ringhals 3, which is a Westinhouse 3- loop PWR within the Vattenfall Group. The fuel is characterized by 17x17 assemblies of AFA type containing 3.80-3.95 w/o 235U and 8 rods containing 2 w/o Gadolinium with an enrichment of 70 w/o 157Gd. The calculations were performed with the Studsvik-Scandpower code package based on the CASMO-4 lattice code and the SIMULATE-3 nodal code. The results are compared to the corresponding calculations for fuel with 5 w/o gadolinium with natural isotopic constitution. The depletion of the cores was done separately for the reference and enriched case. The results show that the gains in average for the five cycles studied are about 70 EFPH per cycle. This is an effect of the lower gadolinium content needed. Also less parasitic absorption of enriched gadolinium in the end of the fuel life contributes to the increased cycle lengths. The abruptly increased reactivity and internal power peaking factor around 10 MWd/kgU do not affect the core design negatively. -
Synthesis and Optical Characterization of Samarium Doped Lanthanum Orthophosphate Nanowires
Materials Transactions, Vol. 56, No. 9 (2015) pp. 1422 to 1424 Special Issue on Nanostructured Functional Materials and Their Applications ©2015 The Japan Institute of Metals and Materials Synthesis and Optical Characterization of Samarium Doped Lanthanum Orthophosphate Nanowires Le Van Vu+1, Duong Thi Mai Huong+2, Vu Thi Hai Yen+2 and Nguyen Ngoc Long Center for Materials Science, Faculty of Physics, VNU University of Science, 334 Nguyen Trai, Thanh Xuan, Hanoi, Vietnam 3+ LaPO4 nanowires doped with 0, 1, 2, 3, 4 and 5 mol% Sm were prepared by co-precipitation technique. These nanowires were studied by X-ray diffraction (XRD), transmission electron microscopy (TEM), photoluminescence (PL), photoluminescence excitation (PLE) spectra and energy-dispersive X-ray spectra (EDS). The PL spectra exhibited 4 groups of emission peaks, which are assigned to the transitions from the 4 6 3+ 3+ excited state G5/2 to the ground states HJ with J = 5/2; 7/2; 9/2 and 11/2ofSm ions. The intensity of PL related to Sm ion reached to a maximum when the Sm doping content was 2 mol%. The PLE spectra show 8 peaks, which are attributed to the absorption transitions from the 6 4 4 6 4 6 4 4 4 H5/2 ground state to the K15/2, D3/2, P7/2, F7/2, P5/2, G9/2, I13/2 and I11/2 excited states. [doi:10.2320/matertrans.MA201526] (Received January 27, 2015; Accepted June 25, 2015; Published August 7, 2015) Keywords: co-precipitation, samarium doped lanthanum orthophosphate, nanowires, photoluminescence 1. Introduction stirring for 3 h at room temperature.